Pedro Uson Junior, MD retweeted
#ICYMI: Germline Cancer Susceptibility Gene Testing in Unselected Patients with Hepatobiliary Cancers: A Multi-Center Prospective Study by @PedroUson, Samadder et al. https://teapawt.org/t.co/SLfd8QEDM9
Pedro Uson Junior, MD retweeted
>15% of #patients w/ #gastriccancer #GEJcancer & #esophagealcancer had #germline PGVs
80% w/ #PARPi #clinicaltrial/management implications
80% missed by @NCCN
#INTERCEPT @PedroUson @J_Samadder @MayoCancerCare @Invitae @DDS_Journal @springerpub
link.springer.com/article/10…
Pedro Uson Junior, MD retweeted
Hot off the Press ...
Circulating Cell-Free Tumor DNA in Advanced #PancreaticCancer identifies Patients With Worse Overall Survival frontiersin.org/article/10.3…
@PedroUson @the_danielahn @drjasonstarr @MiteshBorad @kmody29 @sonbol_bassam @MayoCancerCare @FrontOncology
Pedro Uson Junior, MD retweeted
Replying to @Aiims1742
@Aiims1742 thank you for sharing the findings of this paper in #pancreaticcancer
@MayoCancerCare @PedroUson
Clinical Impact of Pathogenic Germline Variants in #PancreaticCancer
journals.lww.com/ctg/Fulltex…
All 3 @MayoClinic campuses conducted this study following the @NCCN universal germ line testing guidelines
~15% patients had pathogenic germline variants (BRCA2/ATM most common)
Germline cancer susceptibility gene testing in unselected patients with colorectal adenocarcinoma: A multi-center prospective study cghjournal.org/article/S1542…
Pedro Uson Junior, MD retweeted
Replying to @SyedAAhmad5 @JournalofGISurg @timpawlik @HodinRichard @NZyromski @JBMatthews @TomVargheseJr @SWexner
Blinding only one side of the process is problematic. Unblinding reviewers comes w other problems, especially for junior reviewers. Double blinding may be best. Like this piece by @DrNCoburn @VGupta_MD on that issue 👉 journals.lww.com/annalsofsur…
Pedro Uson Junior, MD retweeted
Pedro Uson Junior, MD retweeted
Replying to @agrothey
@agrothey @VPrasadMDMPH No perfect trial design. Limited options in PDAC. POLO trial adds one more and supports a precedent from other BRCA-related cancers. A nicer option over chemotherapy for most patients on a longitudinal basis. A start point to build upon...
Vinay, please.... I have been critical of the POLO trial @EileenMOReilly but this is not “criminal”. We are all trying to move science forward - and POLO with all its faults does that. @OncoAlert
Pedro Uson Junior, MD retweeted
Last but not least #ESMO20 CheckMate577
Given the complex study cohort enrolling >700 patients is a huge accomplishment! Global study 🌎 🤝
Primary endpoint DFS (secondary OS).
Primary endpoint reached with HR 0.69
@OncoAlert 🚨 #immunotherapy – at Munich, Germany
Pedro Uson Junior, MD retweeted
Practice changing 3 month+ OS gain for CPS5 patients in CheckMate649 🏆🏆🏆 Biggest study ever in #stomachcancer! Breaking through the one year barrier is meaningful in gastric cancer trials. #ESMO2020
Pedro Uson Junior, MD retweeted
#Pancsm #ESMO20
#PancreaticCancer remains a devastating disease.
See data presented by @EileenMOReilly discussing negative trials in #pancsm & a potential ways forward.
@OncoAlert 🚨 – at Munich, Germany
Pedro Uson Junior, MD retweeted
Results: CCTG PA.7 in #pancreas #cancer of randomized Gemzar + Nab-P +/- Durvalumab + Treme with no difference in OS (8.8M vs. 9.8M), PFS of (5.4M vs. 5.5M), or RR = 23% vs. 33%. #ESMO20
@PanCAN #clinicaltrials #CancerResearch @VUMC_Cancer @VUMChealth @OncoAlert #immunotherapy
Pedro Uson Junior, MD retweeted
Replying to @myESMO
@myESMO Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer (CRC) - PRODIGE 13 a FFCD phase III trial #ESMO20 by Dr Come Lepage
@OncoAlert @PedroUson @OPENoncology @Epigenomica_mx @trials4now @Kristel_GT
Pedro Uson Junior, MD retweeted
Resposible decision by @US_FDA
FDA Denies Approval of Pembrolizumab/Lenvatinib for Frontline Unresectable HCC targetedonc.com/view/fda-den… via @targetedonc
Pedro Uson Junior, MD retweeted
Replying to @pashtoonkasi @DrR_DUNNE @GABOUALFA @myESMO @marklewismd @Annals_Oncology @OncoAlert @mtmdphd @EileenMOReilly
Line -1 has a negative connotation for a very positive outcome for Atezo Bev
1st Line Atezo Bev
2nd line Up for grabs
Let's not make up lines that are pure fiction
Pedro Uson Junior, MD retweeted
FDA Approves Pembrolizumab for TMB-High Tumors | @OncLive @FDAOncology @OncoAlert @GlopesMd @marklewismd @mtmdphd onclive.com/view/fda-approve…




























